Christopher Dvorak, MD

My Research Interests are divided into 3 areas of focus:

1. Supportive Care (especially Invasive Fungal Infections) following Hematopoietic Stem Cell Transplantation
2. Transplantation for Severe Combined Immunodeficiency
3. Transplantation for Rare Leukemias (JMML and APL)
Education
M.D., 1998 - School of Medicine, Vanderbilt University
B.S., 1994 - Molecular Biology, University of California, San Diego
Websites
Publications
  1. KIR-Favorable TCR-αβ/CD19-Depleted Haploidentical HCT in Children with ALL/AML/MDS: Primary Analysis of PTCTC ONC1401.
  2. Outcomes Following Treatment for Adenosine Deaminase Deficient Severe Combined Immunodeficiency: A Report from the PIDTC.
  3. Granulocyte Transfusions in Patients with Chronic Granulomatous Disease Undergoing Hematopoietic Cell Transplantation or Gene Therapy.
  4. Challenges and Barriers to Adverse Event Reporting in Clinical Trials: A Children's Oncology Group Report.
  5. Population Pharmacokinetics of Melphalan for Pediatric Patients Undergoing Hematopoietic Cell Transplantation.
  6. Pulmonary microbiome and gene expression signatures differentiate lung function in pediatric hematopoietic cell transplant candidates.
  7. A pilot trial of prophylactic defibrotide to prevent serious thrombotic microangiopathy in high-risk pediatric patients.
  8. Association between the magnitude of intravenous busulfan exposure and development of hepatic veno-occlusive disease in children and young adults undergoing myeloablative allogeneic hematopoietic cell transplantation.
  9. Therapy-related myeloid neoplasms resembling juvenile myelomonocytic leukemia: a case series and review of the literature.
  10. Population Pharmacokinetic Model Development of Tacrolimus in Pediatric and Young Adult Patients Undergoing Hematopoietic Cell Transplantation.
  11. Hematopoietic Cell Transplant-Comorbidity Index Score is Correlated with Treatment Related Mortality and Overall Survival following Second Allogeneic Hematopoietic Cell Transplant in Children.
  12. Juvenile myelomonocytic leukemia in the molecular era: a clinician's guide to diagnosis, risk-stratification, and treatment.
  13. The Beginning of the End of Allogeneic Transplantation for Hurler Syndrome?
  14. Infrastructure of Fertility Preservation Services for Pediatric Cancer Patients: A Report From the Children's Oncology Group.
  15. Prospective Evaluation of Galactomannan and (1?3) ß-d-Glucan Assays as Diagnostic Tools for Invasive Fungal Disease in Children, Adolescents, and Young Adults With Acute Myeloid Leukemia Receiving Fungal Prophylaxis.
  16. Poor T-cell receptor β repertoire diversity early posttransplant for severe combined immunodeficiency predicts failure of immune reconstitution.
  17. Comparison of hematopoietic cell transplant conditioning regimens for hemophagocytic lymphohistiocytosis disorders.
  18. NUP98-NSD1 Driven MDS/MPN in Childhood Masquerading as JMML.
  19. A Guidance for Concomitant Drug Reconciliation Prior to Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults.
  20. International retrospective study of allogeneic hematopoietic cell transplantation for activated PI3K-delta syndrome.
  21. Reply to Are we certain that chlorhexidine gluconate bathing is not beneficial in deducing central line associated blood stream infections among children with cancer or undergoing hematopoietic stem cell transplantation?
  22. A Randomized Trial of Caspofungin vs Triazoles Prophylaxis for Invasive Fungal Disease in Pediatric Allogeneic Hematopoietic Cell Transplant.
  23. Transplant-associated thrombotic microangiopathy in pediatric patients: pre-HSCT risk stratification and prophylaxis.
  24. Musculoskeletal impairments in children receiving intensive therapy for acute leukemia or undergoing hematopoietic stem cell transplant: A report from the Children's Oncology Group.
  25. The pulmonary metatranscriptome prior to pediatric HCT identifies post-HCT lung injury.
  26. Vitamin D has no impact on outcomes after HSCT in children-A retrospective study.
  27. A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation.
  28. Correction to: Infections in Infants with SCID: Isolation, Infection Screening and Prophylaxis in PIDTC Centers.
  29. A pragmatic multi-institutional approach to understanding transplant-associated thrombotic microangiopathy after stem cell transplant.
  30. The Relationship Between Busulfan Exposure and Achievement of Sustained Donor Myeloid Chimerism in Patients with Non-Malignant Disorders.
  31. Unknown cytomegalovirus serostatus in primary immunodeficiency disorders: A new category of transplant recipients.
  32. Correction: Chronic Granulomatous Disease-Associated IBD Resolves and Does Not Adversely Impact Survival Following Allogeneic HCT.
  33. Infections in Infants with SCID: Isolation, Infection Screening, and Prophylaxis in PIDTC Centers.
  34. How We Treat Fever and Hypotension in Pediatric Hematopoietic Cell Transplant Patients.
  35. Assessment of provider perspectives on otoprotection research for children and adolescents: A Children's Oncology Group Cancer Control and Supportive Care Committee survey.
  36. Lower Exposure to Busulfan Allows for Stable Engraftment of Donor Hematopoietic Stem Cells in Children with Mucopolysaccharidosis Type I: A Case Report of Four Patients.
  37. Assessment of a Model-Informed Precision Dosing Platform Use in Routine Clinical Care for Personalized Busulfan Therapy in the Pediatric Hematopoietic Cell Transplantation (HCT) Population.
  38. Reduced Toxicity Conditioning for Nonmalignant Hematopoietic Cell Transplants.
  39. Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report.
  40. Practice patterns and incidence of adenovirus infection in allogeneic hematopoietic cell transplant recipients: Multicenter survey of transplant centers in the United States.
  41. Hematopoietic Cell Transplantation in Patients With Primary Immune Regulatory Disorders (PIRD): A Primary Immune Deficiency Treatment Consortium (PIDTC) Survey.
  42. TA-TMA: state of the art for diagnosis and treatment.
  43. Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injury-Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplant.
  44. Chlorhexidine gluconate bathing in children with cancer or those undergoing hematopoietic stem cell transplantation: A double-blinded randomized controlled trial from the Children's Oncology Group.
  45. Extended Follow-up After Hematopoietic Cell Transplantation for I?Ba Deficiency with Disseminated Mycobacterium avium Infection.
  46. The impact of total body irradiation-based regimens on outcomes in children and young adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation.
  47. Effect of Caspofungin vs Fluconazole Prophylaxis on Invasive Fungal Disease Among Children and Young Adults With Acute Myeloid Leukemia: A Randomized Clinical Trial.
  48. Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia.
  49. Comprehensive Prognostication in Critically Ill Pediatric Hematopoietic Cell Transplant Patients: Results from Merging the Center for International Blood and Marrow Transplant Research (CIBMTR) and Virtual Pediatric Systems (VPS) Registries.
  50. Fusion driven JMML: a novel CCDC88C-FLT3 fusion responsive to sorafenib identified by RNA sequencing.
  51. Related and unrelated donor transplantation for ß-thalassemia major: results of an international survey.
  52. Acupressure to Reduce Treatment-Related Symptoms for Children With Cancer and Recipients of Hematopoietic Stem Cell Transplant: Protocol for a Randomized Controlled Trial.
  53. Chronic Granulomatous Disease-Associated IBD Resolves and Does Not Adversely Impact Survival Following Allogeneic HCT.
  54. Molecular assessment of pretransplant chemotherapy in the treatment of juvenile myelomonocytic leukemia.
  55. Risk Factors for Transplant-Associated Thrombotic Microangiopathy after Autologous Hematopoietic Cell Transplant in High-Risk Neuroblastoma.
  56. Pulmonary Metagenomic Sequencing Suggests Missed Infections in Immunocompromised Children.
  57. Autoimmune Cytopenias in Pediatric Hematopoietic Cell Transplant Patients.
  58. Survival Trends in Infants Undergoing Allogeneic Hematopoietic Cell Transplant.
  59. Population Pharmacokinetics of Clofarabine as Part of Pretransplantation Conditioning in Pediatric Subjects before Hematopoietic Cell Transplantation.
  60. Transplant-Associated Thrombotic Microangiopathy in Pediatric Hematopoietic Cell Transplant Recipients: A Practical Approach to Diagnosis and Management.
  61. In ALD, I feel the need for speed.
  62. Low Exposure Busulfan Conditioning to Achieve Sufficient Multilineage Chimerism in Patients with Severe Combined Immunodeficiency.
  63. Determination of melphalan in human plasma by UPLC-UV method.
  64. Newborn Screening for Severe Combined Immunodeficiency and T-cell Lymphopenia in California, 2010-2017.
  65. Hematopoietic stem cell transplantation for CD40 ligand deficiency: Results from an EBMT/ESID-IEWP-SCETIDE-PIDTC study.
  66. Early Plasma Matrix Metalloproteinase Profiles. A Novel Pathway in Pediatric Acute Respiratory Distress Syndrome.
  67. Higher Risks of Toxicity and Incomplete Recovery in 13- to 17-Year-Old Females after Marrow Donation: RDSafe Peds Results.
  68. Bacterial blood stream infections (BSIs), particularly post-engraftment BSIs, are associated with increased mortality after allogeneic hematopoietic cell transplantation.
  69. Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study.
  70. Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors.
  71. Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation.
  72. Identifying clinical practice guidelines for the supportive care of children with cancer: A report from the Children's Oncology Group.
  73. Outcomes after Second Hematopoietic Cell Transplantation in Children and Young Adults with Relapsed Acute Leukemia.
  74. Comment on: Olanzapine for chemotherapy-induced nausea: Lessons learned from child and adolescent psychiatry.
  75. Effect of Levofloxacin Prophylaxis on Bacteremia in Children With Acute Leukemia or Undergoing Hematopoietic Stem Cell Transplantation: A Randomized Clinical Trial.
  76. The genetic landscape of severe combined immunodeficiency in the United States and Canada in the current era (2010-2018).
  77. Veno-occlusive disease after high-dose busulfan-melphalan in neuroblastoma.
  78. Practice pattern changes and improvements in hematopoietic cell transplantation for primary immunodeficiencies.
  79. SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery.
  80. Chronic norovirus infection in primary immune deficiency disorders: an international case series.
  81. Outcome of domino hematopoietic stem cell transplantation in human subjects: An international case series.
  82. Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression.
  83. Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine.
  84. B-cell differentiation and IL-21 response in IL2RG/JAK3 SCID patients after hematopoietic stem cell transplantation.
  85. Late cardiovascular morbidity and mortality following pediatric allogeneic hematopoietic cell transplantation.
  86. Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study.
  87. Metagenomic Sequencing Detects Respiratory Pathogens in Hematopoietic Cellular Transplant Patients.
  88. Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study.
  89. Pediatric Hematopoietic Cell Transplant Patients Who Survive Critical Illness Frequently Have Significant but Recoverable Decline in Functional Status.
  90. Immune reconstitution and survival of 100 SCID patients post-hematopoietic cell transplant: a PIDTC natural history study.
  91. Pulmonary veno-occlusive disease in a pediatric hematopoietic stem cell transplant patient: a cautionary tale.
  92. Neurologic event-free survival demonstrates a benefit for SCID patients diagnosed by newborn screening.
  93. Consensus Report by the Pediatric Acute Lung Injury and Sepsis Investigators and Pediatric Blood and Marrow Transplantation Consortium Joint Working Committees on Supportive Care Guidelines for Management of Veno-Occlusive Disease in Children and Adolesce
  94. Consensus Report by the Pediatric Acute Lung Injury and Sepsis Investigators and Pediatric Blood and Marrow Transplant Consortium Joint Working Committees on Supportive Care Guidelines for Management of Veno-Occlusive Disease in Children and Adolescents:
  95. Reducing Second Gram-Negative Antibiotic Therapy on Pediatric Oncology and Hematopoietic Stem Cell Transplantation Services.
  96. Opening Marrow Niches in Patients Undergoing Autologous Hematopoietic Stem Cell Gene Therapy.
  97. Consensus Report by Pediatric Acute Lung Injury and Sepsis Investigators and Pediatric Blood and Marrow Transplantation Consortium Joint Working Committees: Supportive Care Guidelines for Management of Veno-Occlusive Disease in Children and Adolescents, P
  98. Pharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant Recipients.
  99. Burden of illness associated with sinusoidal obstruction syndrome/veno-occlusive disease in patients with hematopoietic stem cell transplantation.
  100. Extracorporeal life support survival in a pediatric hematopoietic cellular transplant recipient with presumed GvHD-related fulminant myocarditis.
  101. Multisite external validation of a risk prediction model for the diagnosis of blood stream infections in febrile pediatric oncology patients without severe neutropenia.
  102. Unconditioned unrelated donor bone marrow transplantation for IL7Ra- and Artemis-deficient SCID.
  103. Safety of pre-emptive donor lymphocyte infusions (DLI) based on mixed chimerism (MC) in peripheral blood or bone marrow subsets in children undergoing hematopoietic stem cell transplant (HSCT) for hematologic malignancies.
  104. Eosinophilic Pustular Folliculitis in Children after Stem Cell Transplantation: An Eruption Distinct from Graft-Versus-Host Disease.
  105. Treatment of infants identified as having severe combined immunodeficiency by means of newborn screening.
  106. Early mixed chimerism-based preemptive immunotherapy in children undergoing allogeneic hematopoietic stem cell transplantation for acute leukemia.
  107. A Multicenter Study of Bacterial Blood Stream Infections in Pediatric Allogeneic Hematopoietic Cell Transplantation Recipients: The Role of Acute Gastrointestinal Graft-versus-Host Disease.
  108. Pre-existing invasive fungal infection is not a contraindication for allogeneic HSCT for patients with hematologic malignancies: a CIBMTR study.
  109. Musical chairs: in utero HCT via mobilization.
  110. Hematopoietic stem cell transplant in patients with activated PI3K delta syndrome.
  111. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis.
  112. Long-term outcomes of 176 patients with X-linked hyper-IgM syndrome treated with or without hematopoietic cell transplantation.
  113. Evaluation of Pre-Hematopoietic Cell Transplantation (HCT) Brain MRI and Neurologic Complications of Pediatric Patients Undergoing HCT for Hematologic Malignancies.
  114. Severe, persistent, and fatal T-cell immunodeficiency following therapy for infantile leukemia.
  115. Transplacental maternal engraftment and posttransplantation graft-versus-host disease in children with severe combined immunodeficiency.
  116. Risk of serious bloodstream infections is low in pediatric hematopoietic stem cell transplant (HSCT) recipients with fevers due to antithymocyte globulins and alemtuzumab.
  117. Safe and Effective Prophylaxis with Bimonthly Intravenous Pentamidine in the Pediatric Hematopoietic Stem Cell Transplant Population.
  118. The incidence, mortality and timing of Pneumocystis jiroveci pneumonia after hematopoietic cell transplantation: a CIBMTR analysis.
  119. Plasma angiopoietin-2 outperforms other markers of endothelial injury in prognosticating pediatric ARDS mortality.
  120. Classification of treatment-related mortality in children with cancer: a systematic assessment.
  121. New Insights Into Multicenter PICU Mortality Among Pediatric Hematopoietic Stem Cell Transplant Patients.
  122. Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research.
  123. The syndrome of hemophagocytic lymphohistiocytosis in primary immunodeficiencies: implications for differential diagnosis and pathogenesis.
  124. Transplantation Outcomes for Children with Hypodiploid Acute Lymphoblastic Leukemia.
  125. Population pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: a model-based dosing algorithm for personalized therapy and implementation into routine clinical use.
  126. The Sequence of Cyclophosphamide and Myeloablative Total Body Irradiation in Hematopoietic Cell Transplantation for Patients with Acute Leukemia.
  127. Primary graft failure after myeloablative allogeneic hematopoietic cell transplantation for hematologic malignancies.
  128. Hematopoietic Stem Cell Transplantation for Severe Combined Immunodeficiency.
  129. Repeat blood cultures in children with persistent fever and neutropenia: Diagnostic and clinical implications.
  130. Juvenile myelomonocytic leukemia.
  131. Chimerism-based pre-emptive immunotherapy with fast withdrawal of immunosuppression and donor lymphocyte infusions after allogeneic stem cell transplantation for pediatric hematologic malignancies.
  132. Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia.
  133. The safety of olanzapine in young children: a systematic review and meta-analysis.
  134. TNF-receptor inhibitor therapy for the treatment of children with idiopathic pneumonia syndrome. A joint Pediatric Blood and Marrow Transplant Consortium and Children's Oncology Group Study (ASCT0521).
  135. Bedside to bench in juvenile myelomonocytic leukemia: insights into leukemogenesis from a rare pediatric leukemia.
  136. Comparison of outcomes of hematopoietic stem cell transplantation without chemotherapy conditioning by using matched sibling and unrelated donors for treatment of severe combined immunodeficiency.
  137. Transplantation outcomes for severe combined immunodeficiency, 2000-2009.
  138. A Prospective, International Cohort Study of Invasive Mold Infections in Children.
  139. Outcomes after hematopoietic stem cell transplantation for children with I-cell disease.
  140. Treatment of hepatoblastoma with high-dose chemotherapy and stem cell rescue: the pediatric blood and marrow transplant consortium experience and review of the literature.
  141. A trial of alemtuzumab adjunctive therapy in allogeneic hematopoietic cell transplantation with minimal conditioning for severe combined immunodeficiency.
  142. A trial of plerixafor adjunctive therapy in allogeneic hematopoietic cell transplantation with minimal conditioning for severe combined immunodeficiency.
  143. Simultaneous determination of fludarabine and clofarabine in human plasma by LC-MS/MS.
  144. Effect of body mass in children with hematologic malignancies undergoing allogeneic bone marrow transplantation.
  145. Juvenile myelomonocytic leukemia: molecular pathogenesis informs current approaches to therapy and hematopoietic cell transplantation.
  146. Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: the Primary Immune Deficiency Treatment Consortium experience.
  147. SCID patients with ARTEMIS vs RAG deficiencies following HCT: increased risk of late toxicity in ARTEMIS-deficient SCID.
  148. Primary Immune Deficiency Treatment Consortium (PIDTC) report.
  149. Effect of weight and maturation on busulfan clearance in infants and small children undergoing hematopoietic cell transplantation.
  150. The natural history of children with severe combined immunodeficiency: baseline features of the first fifty patients of the primary immune deficiency treatment consortium prospective study 6901.
  151. Children's Oncology Group's 2013 blueprint for research: stem cell transplantation.
  152. Results from a prospective, international, epidemiologic study of invasive candidiasis in children and neonates.
  153. Haploidentical related-donor hematopoietic cell transplantation in children using megadoses of CliniMACs-selected CD34(+) cells and a fixed CD3(+) dose.
  154. Clinical outcome in IL-10- and IL-10 receptor-deficient patients with or without hematopoietic stem cell transplantation.
  155. Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution.
  156. Impact of immune modulation with in vivo T-cell depletion and myleoablative total body irradiation conditioning on outcomes after unrelated donor transplantation for childhood acute lymphoblastic leukemia.
  157. Massage for children undergoing hematopoietic cell transplantation: a qualitative report.
  158. Hematopoietic cell transplant and use of massage for improved symptom management: results from a pilot randomized control trial.
  159. National Cancer Institute, National Heart, Lung and Blood Institute/Pediatric Blood and Marrow Transplantation Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: the need for pediatric-s
  160. Complications of transplant for nonmalignant disorders: autoimmune cytopenias, opportunistic infections, and PTLD.
  161. Antifungal prophylaxis in pediatric hematology/oncology: new choices & new data.
  162. Epidemiology and potential preventative measures for viral infections in children with malignancy and those undergoing hematopoietic cell transplantation.
  163. Prevention of bacterial infection in pediatric oncology: what do we know, what can we learn?
  164. NCI, NHLBI/PBMTC first international conference on late effects after pediatric hematopoietic cell transplantation: endocrine challenges-thyroid dysfunction, growth impairment, bone health, & reproductive risks.
  165. NCI, NHLBI first international consensus conference on late effects after pediatric hematopoietic cell transplantation: state of the science, future directions.
  166. Outcome of myeloablative conditioning and unrelated donor hematopoietic cell transplantation for childhood acute lymphoblastic leukemia in third remission.
  167. Short tandem repeat and human leukocyte antigen mutations or losses confound engraftment and typing analysis in hematopoietic stem cell transplants.
  168. Severe neonatal congenital erythropoietic porphyria.
  169. Safety of the live, attenuated varicella vaccine in pediatric recipients of hematopoietic SCTs.
  170. Radiosensitive severe combined immunodeficiency disease.
  171. The tortoise and the hare: slow and steady stem cells win the race.
  172. Development of herpes simplex virus stomatitis during receipt of cidofovir therapy.
  173. Clinical and immunologic outcomes following haplocompatible donor lymphocyte infusions.
  174. Primary graft failure after umbilical cord blood transplant rescued by parental haplocompatible stem cell transplantation.
  175. Pathological evidence of Wolman's disease following hematopoietic stem cell transplantation despite correction of lysosomal acid lipase activity.
  176. Safety of hematopoietic stem cell transplantation in children less than three years of age.
  177. High-dose chemotherapy followed by stem cell rescue for high-risk germ cell tumors: the Stanford experience.
  178. Megadose CD34(+) cell grafts improve recovery of T cell engraftment but not B cell immunity in patients with severe combined immunodeficiency disease undergoing haplocompatible nonmyeloablative transplantation.
  179. Hematopoietic stem cell transplant for pediatric acute promyelocytic leukemia.
  180. Maternal T-cell engraftment associated with severe hemophagocytosis of the bone marrow in untreated X-linked severe combined immunodeficiency.
  181. Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases.
  182. Increasing mixed chimerism and the risk of graft loss in children undergoing allogeneic hematopoietic stem cell transplantation for non-malignant disorders.
  183. Liposomal amphotericin B associated with severe hyperphosphatemia.
  184. Hematopoietic stem cell transplantation for primary immunodeficiency disease.
  185. Reinduction of relapsed acute promyelocytic leukemia with ATRA and low dose antimetabolite-based chemotherapy.
  186. Optimizing care for GI disorders in children after hematopoietic stem cell transplantation.
  187. Use of intravenous mycophenolate mofetil for graft-versus-host disease prophylaxis in an allogeneic hematopoietic stem cell transplant recipient with an allergic reaction to cyclosporine and tacrolimus.
  188. Risks and outcomes of invasive fungal infections in pediatric patients undergoing allogeneic hematopoietic cell transplantation.
  189. Hospital resource utilization among patients with sickle cell disease.
  190. Synthesis and central nervous system properties of 2-[(alkoxycarbonyl)amino]-4(5)-phenyl-2-imidazolines.